REAL-WORLD CLINICAL OUTCOMES ASSOCIATED WITH CANAGLIFLOZIN IN PATIENTS
AGED 65 YEARS AND OLDER WITH TYPE 2 DIABETES MELLITUS IN SPAIN: THE OLD
REAL-WECAN STUDY.
Abstract
Abstract Objectives The observational REAL WECAN study showed that
canagliflozin 100 mg (CANA100) as add-on therapy, and canagliflozin 300
mg (CANA300), switching from prior SGLT-2i therapy, significantly
improved several cardiometabolic parameters in patients with T2DM. The
aim of this sub-analysis was to assess the effectiveness and safety of
canagliflozin in patients aged >65 years. The primary
outcome of the study was the mean change in HbA1c over the follow-up
time. Materials and Methods 583 patients met the inclusion criteria
(39.5% > 65 years), 279 in the CANA100 cohort (36.9 %
> 65 years, mean HbA1c 8.05%) and 304 in the CANA300
cohort (41.8 % > 65 years, mean HbA1c 7.51%). Results In
the CANA100 cohort, older patients showed significant reductions in
HbA1c (-0.78%) and weight (-4.5 kg). Patients aged >65
years switching to CANA300 experienced a significant decrease in HbA1c
(-0.27%) and weight (-2.1 kg). There were no significant differences in
HbA1c and weight reductions when the cohorts of patients <65
and >65 years were compared in a multiple linear regression
model. The safety profile of canagliflozin was similar in both age groups.
Conclusion These findings support canagliflozin as an effective
therapeutic option for older adults with T2DM